Answers are grounded in this paper and cite their sources.
Case report reveals fatal interstitial pneumonitis in a patient following carmustine treatment, suggesting careful monitoring is essential.
Carmustine (BCNU) is a nitrosourea DNA-alkylating agent widely used in the treatment of lymphoma, brain tumors, melanoma, and as conditioning therapy prior to stem cell transplantation. Pulmonary toxicity occurs in approximately 10-30% of patients and is associated with higher cumulative doses (>1000-1500 mg/m²), preexisting lung disease, prior chest radiation, and concurrent use of other cytotoxic agents. We present a 59-year-old female with primary central nervous system lymphoma (PCNSL) who developed acute hypoxic respiratory failure three weeks after receiving carmustine (400 mg/m²) and thiotepa-conditioned autologous hematopoietic stem cell transplantation (HSCT). Baseline pulmonary function testing prior to HSCT was normal: forced vital capacity (FVC) 124% predicted, forced expiratory volume in 1 second (FEV1) 123% predicted, FEV1/FVC 81%, and hemoglobin-adjusted diffusion capacity for carbon monoxide (DLCO) 86% predicted. On admission, she reported two weeks of progressive dyspnea and dry cough. Vitals showed hypoxia (SpO2 83% on room air) requiring high-flow nasal cannula, respiratory rate 29 breaths/min, pulse 85 bpm, blood pressure 111/49 mmHg, and temperature 98.6 °F. Physical examination revealed diffuse bibasilar coarse crackles and increased work of breathing. Laboratory findings included WBC 11.33 K/cu mm (neutrophils 94.4%, lymphocytes 2%), hemoglobin 8.2 g/dL, and platelets 36 K/cu mm. Venous blood gas demonstrated a mixed respiratory alkalosis and metabolic acidosis (pH 7.40, pCO2 32 mmHg, HCO3 20 mmol/L). Bronchoalveolar lavage showed WBC 1,625 cu mm (neutrophils 69%, lymphocytes 17%) with negative cytology and infectious studies. Comprehensive infectious workup, including evaluation of opportunistic pathogens, was negative. Chest CT revealed diffuse bilateral ground-glass opacities involving all lobes. Despite treatment with high-dose corticosteroids (up to 2 mg/kg), there was no clinical improvement. Her course was complicated by spontaneous pneumothorax, and she ultimately died from progressive interstitial pneumonitis. BCNU-induced interstitial pneumonitis is thought to result from glutathione depletion, oxidative stress, and induction of fibrogenic cytokines in alveolar macrophages and type II pneumocytes. Although the safe threshold for BCNU remains debated, pulmonary toxicity has been reported at doses as low as 600 mg/m², particularly among female patients. Preventive measures for patients receiving carmustine include serial DLCO monitoring and initiation of corticosteroids if a ≥ 10% decline is observed. Progressive pneumonitis is often refractory to corticosteroids, with an estimated mortality of 50%. Early recognition and prompt corticosteroid initiation may improve outcomes. This case underscores the need to consider BCNU-induced pulmonary toxicity even at doses below 1000 mg/m² and highlights the importance of vigilant monitoring and early intervention.
No takes yet. Share an insight, caveat, or question.
Kamel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: